Icalcaprant

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Major Depressive DisorderBipolar I Disorder

120 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

1

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

122

Ketalar

Boehringer Ingelheim

Phase 3

33

Lithobid

SSolvay Pharmaceuticals

Phase 3

14

Clozaril

LLife Extension Foundation Inc.

Phase 3

15

Sunosi

AAxsome Therapeutics, Inc.

Phase 3

16

Psilocybin

COMPASS Pathways

Phase 3

117

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

28

Aticaprant

Johnson & Johnson

Phase 3

49

Selective Serotonin Reuptake Inhibitor

Johnson & Johnson

Phase 3

210

Azetukalner

XXenon Pharmaceuticals Inc.

Phase 3

3Show 36 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Adverse Events1 trial

A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants

Completed·AbbVie·Phase 1·NCT06722417·16 enrolled

Major Depressive Disorder1 trial

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

Recruiting·AbbVie·Phase 2·NCT07276997·195 enrolled

Adult1 trial

A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Through the Body in Healthy Adult Participants

Completed·AbbVie·Phase 1·NCT06722430·12 enrolled

Bipolar I Disorder1 trial

A Phase 2, Multicenter, 6-Week, Double Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Icalcaprant in Subjects With Bipolar Depression

Recruiting·AbbVie·Phase 2·NCT06696755·195 enrolled

Details

Drug Info

Related News